Theradaptive Inc, spun out of MIT and currently resident in JPod Philadelphia., is developing a therapeutic delivery platform that promotes targeted native tissue repair. With a focus on novel therapeutics for those having degenerative diseases and/or trauma, indocations of the platform include spinal fusion, trauma repair, dental repair, and complex cartilage repair. Permitting the design of implantable therapeutic delivery devices that integrate into native tissue and can lead to superior outcomes, Theradaptive can convert any recombinant protein into a variant that that can be "painted" onto materials. This capability makes possible a process of beig able to coat implants, devices, and injectable carriers so as to deliver a therapeutic directly to where it is needed and predictably to control the delivery over long periods of time and within known dosing parameters.
